康弘药业(002773.SZ)：康柏西普眼用注射液收到临床试验补充申请批准通知书

Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology Co., has received approval from the National Medical Products Administration for a clinical trial supplement application for its high-dose injection of Conbercept, a first-class biopharmaceutical with independent intellectual property rights [1] Group 1 - The Conbercept eye injection is a self-developed innovative drug that effectively binds to VEGF in blood and tissues, blocking signals that promote neovascularization [1] - The clinical application of high-dose Conbercept is expected to enhance patient compliance and reduce medical burdens [1]